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Background: Counterpulsation devices (CPD) require electrocardiogram (ECG) 
lead implantation for timing device filling and ejection with the native heart. Non-
implantable leads limit the scope of CPD treatment to short-term therapy. 
Standard transvenous/epicardial ECG leads increase the invasiveness of 
therapy.  
      
Methods: To overcome these limitations, subcutaneous ECG leads were tested 
in chronic (n=6) and acute (n=5) bovine models. ECG waveforms from clinical-
grade epicardial (control) leads and subcutaneous (test) leads were 
simultaneously recorded resulting in 830 data epochs (30-s each) for a total of 
44,614 heart beats. Device triggering using R-wave detection was calculated for 
each lead type and compared. Additionally, the hemodynamic benefits of CPD 
with aortic cannulation (n=5) was investigated during normal and 
pharmacologically-induced heart failure, hypertension, and hypotension test 
conditions.  
 
Results: The subcutaneous leads provided 98.9% positive predictive 
value and 98.9% sensitivity compared to the epicardial ECG leads. Out of 40 
subcutaneous leads implanted in chronic animals, lead migration (sensing-end 
movement >0.5cm, n=1) and lead fracture (n=1) were observed in two leads but 





cannulated to the aorta showed diminished left ventricular (LV) external work, LV 
end diastolic volume, and LV end systolic volume during 1:1 support compared to 
baseline in pharmacologically induced heart failure (HF). The CPD also 
augmented cardiac output, aortic mean pressure, aortic pulse pressure, and 
mean coronary artery flow.   
 
Conclusion: These findings demonstrate the efficacy of chronic, subcutaneous 
ECG leads for CPD timing. The hemodynamic feasibility of the CPD cannulated 
to the aorta is equivalent or better than subclavian artery cannulation because of 
the proximity to the heart, which may increase the size of CPD patient population 
for warranted cases.  
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 Heart Failure (HF) is an incurable, progressive disease that afflicts 
5,100,000 people in the United States with a 50% mortality rate within 5 years. 
According to the Center for Disease Control and Prevention, HF costs the nation 
$32 billion per year including the cost of medication, medical services, and 
missed days of work for HF patients. The prevalence of heart failure continues to 
rise worldwide (~1,000,000 new patients per year) as the causes for heart failure 
such as obesity, coronary artery disease, and hypertension persist [5].  
  
 Currently, pharmacological agents including using beta blockers, diuretics, 
and ACE inhibitors is the preferred treatment option for HF patients until HF 
progresses to an extent that a more aggressive therapy such as heart 
transplantation or mechanical assist device therapy is warranted. Even though 
the US averaged $8,915 per person on health care in 2012, the favorable 
outcomes for HF patients are low [6]. Muntwyler J, and colleagues reported one 
year mortality rates were 7.1%, 15.0%, and 28.0% for NYHA Class II, III, and IV, 
respectively [7]. Approximately 30% mortality was reported at two years post 
diagnosis in the RALES trial [8]. To combat this poor prognosis, heart 





is considered the best form of end-stage HF therapy for long-term survival. 
However, the supply of donor hearts (~2,300/year in the US) remains relatively 
low while the demand continuously rises [9, 10]. 
 
 Due to the shortage of available donor organs, alternative therapies such as 
mechanical circulatory support (MCS) device implantation are needed. This 
clinical need has led to significant research and development of cardiac assist 
devices for destination therapy (support until death) and bridge to transplant 
therapy (support until organ transplantation is available). Currently, for every 
donor heart successfully transplanted, approximately two MCS devices are 
placed in HF patients. The average cost of left ventricular assist devices is 
$67,085 [11], which limits the use of these devices in developing countries. In 
order expand the patient population for MCS therapy, a significant reduction in 
cost as well as risks associated with surgical implantation is required. Current 
chronic MCS devices require invasive surgical procedures (thoracotomies or 
sternotomies) and the use of Cardiopulmonary Bypass. These procedures 
involve risks of infection and other post-operative complications such as stroke 
and device thrombosis. Therefore, countries worldwide are slow to adopt MCS 









Intra-Aortic Balloon Pump 
 
Moulopoulos, et al. developed a prototype of an Intra-Aortic Balloon Pump 
(IABP) in 1962. This device paved the way for counterpulsation as a means of 
MCS therapy that is cost-effective ($800) [13]. Worldwide, IABP is implanted in 
over 160,000 patients per year and is effective in the treatment of cardiogenic 
shock and acute heart failure [14, 15]. IABP is a balloon which is surgically 
inserted into the descending aorta via access of the femoral artery using a 
modified Seldinger’s technique. Counterpulsation therapy is attained by rapidly 
inflating the IABP immediately after the dicrotic notch and quickly deflating the 
balloon just prior to ventricular systole. 
 
The rapid inflation of the balloon increases the aortic diastolic pressure 
which improves end-organ perfusion and coronary perfusion (up to 100%) [16-
21]. IABP deflation prior to ventricular systole decreases the ejection pressure of 
the native ventricle, reducing after-load and left ventricular external work (LVEW) 
[16, 22, 23]. The LV peak systolic pressure is reduced by up to 15% and the LV 
end diastolic pressure is reduced by approximately 30% [16, 19, 24]. Among 
other benefits is an increase in cardiac output and stroke volume, a decrease in 
heart rate, more efficient metabolic function, and improved end organ perfusion 
and function [25, 26]. IABP implantation is less invasive and consequently has 
fewer intra- and post-operative complications compared to ventricular assist 





patients receiving treatment. There is a critical clinical need to develop 
counterpulsation therapy for chronic and ambulatory use [19, 20, 22, 23, 27]. 
 
Synchronous Counterpulsation Devices 
 
 A number of devices have been developed to provide chronic 
counterpulsation including C-Pulse (Sunshine Medical, Eden Prairie MN), 
CardioVAD (LVAD Technologies, Detroit MI), and Symphony (Abiomed Inc., 
Danvers, MA) [28]. The C-Pulse is a non-blood contacting cuff that is implanted 
around the ascending aorta. The CardioVAD is a blood-contacting polyurethane 
sac that replaces a portion of the descending aorta. Both of these devices require 
the use of thoracotomies and cardiopulmonary bypass for implantation. Because 
LVAD Technologies and Sunshine Medical removed the minimally invasive 
quality of IABP when designing CardioPlus and Sunshine Heart, these devices 
now compete against other invasive MCS devices and have not been widely 
accepted clinically. However, Jeevanandam et al. have demonstrated the clinical 
benefits of the CardioPlus device such as increased cardiac output and end 
organ perfusion [28, 29]. Symphony is a 32 ml device that is implanted in the 











A novel counterpulsation device was developed by SCR Inc. (Louisville, 
KY) in partnership with researchers at the University of Louisville [10]. This 
device is currently undergoing pre-clinical trials[4]. It consists of a 30-ml 
chamber, driveline, and outflow graft. The 30-ml chamber has a blood side and 
air side that is separated by a membrane. The 30-ml chamber sits in the 
pacemaker pocket of the right chest (figure 1). The driveline exits near the 
bottom right side of the thoracic cavity. The outflow graft made of ePTFE was 
designed to connect the 30-ml chamber to the right subclavian artery [3, 30]. The 
device is pneumatically driven. Air is pumped in between the outer hard shell and 
the inner membrane causing CPD ejection. This air is evacuated from the CPD 
chamber during CPD filling. In contrast to IABP, the CPD fills during ventricular 
systole and empties blood during diastole.  
 
Figure 1. CPD sits in a HF patient’s right side underneath the Pectoralis 
muscle via an infraclavicular incision. CPD is surgically anastomosed to 
the right subclavian artery. The pump fills during systole and empties 






Giridharan, et al. demonstrated equivalent or better hemodynamic benefits 
with the CPD compared to 40-ml IABP in a computer simulation model of the 
human circulatory system (Figure 2) [3]. Bartoli, et al. demonstrated a reduction 
in LV oxygen consumption with the CPD compared to 40-ml IABP in a bovine 
model (Figure 3). In addition to better hemodynamic benefits, the CPD 
implantation is less invasive as it can be implanted in the right pacemaker pocket 
without the need to access the thoracic cavity of the patient. Importantly, it has 
the potential for chronic and ambulatory therapy as the device can be driven by a 
portable pneumatic driver weighing ~5 lbs. A significant distinction between an 
IABP and the CPD is that the IABP displaces blood in the native aorta while the 
CPD moves blood in and out of the subclavian artery. This enables the ejection 
and filling phases of the CPD to be longer than the balloon inflation and deflation 
phases of the IABP. Faster balloon deflation is required in IABP to prevent 
obstruction of the aorta during ventricular systole. This rapid deflation leads to 
reverse coronary flow which diminishes myocardial perfusion augmentation and 








Figure 2. Giridharan, et al. demonstrated equivalent or better hemodynamic benefits with 
the 30-ml CPD compared to 40-ml IABP. These pressure volume loops compare baseline 
heart failure (solid) to the 30-ml CPD with early filling late ejection (dashed) and late filling 
early ejection (dotted), and 40-ml IABP operating with early filling early ejection (dash-dot). 
These data indicate lower mean ejection LV Pressure (LVP) and external work (LVEW) with 
early filling late ejection algorithm compared with early filling early ejection and late filling 






Figure 3. Mean ± standard error for hemodynamic parameters during baseline, 
counterpulsation device (CPD) support and intra-aortic balloon pump (IABP) support in a 
bovine animal study during pharmacologically induced hypertension, hypotension, and 
heart failure. LVEW, left ventricular external work; CAFd/LVEW, diastolic coronary artery 
flow normalized to left ventricular external work; LVO2 Consumption, left ventricular 
oxygen consumption during 1:1 support (IABP or CPD) normalized to baseline for that 





CPD Anastomosis  
 
 CPD was originally developed to be anastomosed to a subclavian artery 
that has a minimum diameter of 8 mm. CPD implantation is contraindicated for 
patients with subclavian artery diameters of less than 8 mm as it cannot fully fill 
and eject, leading to blood stasis and device thrombosis. The subclavian artery 
size limits the number of patients that could benefit from CPD therapy [24, 25]. 
Therefore, as an alternative to the subclavian artery graft site, an aortic cannula 
was developed to expand the patient population to individuals with a small 
subclavian artery.  Demonstrating the feasibility of the aortic anastomosis is one of 




ECG signal is required to time CPD filling and ejection. Epicardial ECG 
leads increase the complexity of surgical implant and the risks of infection and/or 
micro-shocks. In order to remove these unwanted risks, an alternative approach 
is required to acquire ECG data while retaining signal fidelity. If the measured 
ECG signal is not adequate or if the CPD is not synchronized with the native 
heart, the CPD may increase ventricular workload and diminish myocardial 
perfusion. Therefore, it is important to find a long-term, reliable solution to 






Besides the use of epicardial leads, other forms of ECG monitoring have 
been considered for CPD [31]. For short-term devices such as IABP, surface 
electrodes (3- to 12-lead configuration) are often used, but these leads may be a 
significant clinical challenge due to motion artifacts and frequent need to replace 
surface electrodes, especially in ambulatory patients  [32]. Alternatively, leads 
can be placed intravenously into the coronary sinus, which requires fluoroscopy 
and introduces additional risks to the patient (dislodgment, fracture, thrombosis, 
and infection) [15, 33, 34]. To overcome the limitations of current approaches, an 
alternative subcutaneous lead system was developed. 
 
Subcutaneous ECG Lead Development 
 
Subcutaneous ECG leads were developed to provide high-quality signal, 
and remove some of the negative effects of more invasive monitoring systems 
[35-37]. Subcutaneous refers to the area of lead implantation right beneath the 
skin. When joined with devices that reside in the pacemaker pocket of the right 
chest, subcutaneous lead placement over the right chest as shown in Figure 4 








Figure 4. Subcutaneous lead placement in bovine (left) and their analogous 
placement in humans (right) [4].  
 
SCR, Inc. completed the engineering development for integrated 
subcutaneous ECG leads, which consisted of two generations of development as 
shown in Figures 5-6. Fabrication was completed by OSCOR (Palm Harbor, FL). 
The current subcutaneous ECG lead configuration consists of four individual 
leads integrated into a single, electrically isolated cable. Each lead has a 
transducer on its distal end (ECG sensing) and a single connector on the 
proximal end that is attached to a signal conditioning and processing module that 
generates an ECG waveform used to trigger and control the CPD. Each lead 
uses a tine for fixation and a 1-cm exposed, non-insulated section for sensing 
cardiac electric potential. Each of the four sensors is on a 25cm length lead to 
provide maximum flexibility and separation distance of up to 50cm between a 
pair of sensors. A separation of 15 cm enables detection of a voltage differential 
(ECG) between paired sensors. The second group of four sensors provides a 
back-up ECG signal in the unexpected event of lead migration or fracture in two 





a single silicone coated cable and integrated into a four-pin LEMO male 
connector (PEI-Genesis), which is mated to a female receptor for ECG signal 
conditioning and processing. The LEMO connectors have a threaded enclosure 
as well as an extended end to provide strain-relief [32, 38]. 
 
 
Figure 5. Photograph of first generation subcutaneous ECG leads 
fabricated by OSCOR and successfully tested in bovine model. The early 
lead design did not include tunneling needle and fixation tine, but 




Figure 6. Photo of current ECG lead configuration complete with LEMO 
connector and strain relief (left) as well as tunneling needle (green arrow) 






 Warren, et al. tested the performance of the previous generation 
subcutaneous lead system (6 bi-polar leads) in in-vivo animal experiments and 
found the subcutaneous leads to provide accurate and reliable R-wave detection 
as well as minimal lead migration, damage, and infection [4]. The lead has been 
redesigned to be unipolar and the lead configuration has been simplified to 4 
leads. The primary objective of this thesis was to test the new lead design and 
configuration in acute bovine and chronic IHF bovine models. A secondary 
objective of the thesis was to demonstrate the hemodynamic feasibility of aortic 
cannulation of the CPD. The experimental design is shown in Figure 7. 
 
















The objectives of this study were to 1) demonstrate chronic subcutaneous 
lead efficacy in providing reliable cardiac signaling for proper device triggering and 
2) quantify the amount of lead migration or other adverse events in long-term 
implantable subcutaneous ECG leads in a chronic ischemic heart failure (IHF) 
model. The study outline is shown in Table 1. Calves first underwent ischemic 
heart failure (IHF) induction procedures (n=6). IHF calves and control (non-IHF 
animal, n=1) were allowed to rest for 45 to 90 days in order to mature into a state 
of advanced heart failure. Next, CPD and ECG lead implantation was performed. 
ECG waveforms were collected using both epicardial and subcutaneous leads. At 
the end of each experiment, calves were euthanized. If a calf died before data 
could be acquired, then that calf was not averaged into the results. 
 
A bovine model was selected because the anatomy of the heart and 
vasculature is similar to that of humans and bovine are more docile compared to 
porcine or ovine models when using devices with many externalized components. 
All animals used were cared for in accordance with the University of Louisville 





Experimental procedures were approved by the UofL Institutional Animal Care and 










1 1 day 1/30/14 1/30/14 died during surgery 
2 10 days 5/12/14 5/20/14 died early from heart failure 
3 30 days 9/30/14 10/30/14 full term 
4 30 days 9/10/14 10/10/14 full term 
5 10 days 11/20/14 11/30/14 
euthanized early for pain 
management reasons 
6 31 days 1/8/15 2/9/15 full term 
Table 1. Summary of electrocardiogram (ECG) lead efficacy and lead 
migration testing in a bovine model of ischemic heart failure 
implanted with a CPD anastomosed to the aorta. 
 
MATERIALS AND METHODS 
 
IHF Induction Procedure 
 
In a bovine model, IHF was induced (n=5) along with a control (non-IHF, 
n=1) for preparation of CPD implantation. Male Jersey calves (Oak Hill Genetics, 
Ewing, IL) weighing 60 kg on arrival from vendor were first quarantined for 14 days 
and treated with preventative medicine: Panacur (10mg/kg S.Q.), Marquis Paste 
(20mg/kg, P.O.), Iron Dextran (2.0ml I.M.), Ivomec (1ml/50ky S.Q.), and Excenel 
(2.2mg/kg S.Q.). After passing quarantine, calves underwent cardiac 
catheterization and IHF induction procedures using a target dose of polystyrene 
embolization solution (1.3% 90μm microsphere solution). This solution was mixed 
with equal amounts of saline and administered at a dose of 0.17 ml per kilogram of 





For IHF induction procedures, food and water was withheld for 20 hours 
before surgery and the calves were given a Fentanyl transdermal patch for 
analgesia. At the time of surgery, general anesthesia was administered with 
Ketamine 4mg/kg and Valium 0.4mg/kg intravenously (IV) and later with 
Isoflurane. External ECG leads were sutured to the calves for ECG monitoring 
and pulse oximeters were used for intra-operative diagnostics. The following 
drugs and fluids were used as necessary under the control of an anesthesiologist 
to provide intraoperative support to the animal: Amiodarone, Lidocaine, 
Dobutamine, Phenylepinephrine, Lactated Ringers Solution, Vitamin B Complex 
Solution, Magnesium Sulfate, and Potassium Chloride. Every stage of the 
procedure was carried out aseptically. A 3-4cm incision was made in the jugular 
furrow.  An AccessTM Vascular Access Port (VAP) was inserted into the jugular 
vein. The VAP was tested for patency, flushed with 10ml saline, and locked with 
taurolidine-citrate catheter solution. The VAP port was placed into the pocket and 
secured to the muscle with 2-0 Vicryl sutures.  An arteriotomy was performed 
and a catheter was placed in the carotid artery and secured. Patency was 
achieved and the catheter was connected to a pressure transducer line for intra-
operative monitoring.  A cordis sheath was placed into the carotid artery using 
the modified Seldinger’s technique.  Upon cardiac catheterization, spheres 90 
microns in diameter were injected down the left anterior descending and 
circumflex coronary arteries of the calf to induce heart failure. Upon completion of 
the embolization procedure, the cordis sheath was removed and the arteriotomy 





of 45 to 90 days in order to mature into a state of advanced heart failure. Once 
heart failure was diagnosed by an ejection fraction of less than 35% the calves 
underwent a CPD implant procedure.  
 
CPD, Subcutaneous, and Epicardial Lead Implant Procedure 
 
The CPD implant procedure was similar to the embolization procedure in 
terms of pharmaceutical use, vascular access, and the steps taken for intra-
operative monitoring. However, Succinylcholine (30mg) was given before the 
implant and a 25 cm incision was made over the 5th rib.  The 5th rib was then 
removed and two rib retractors were used for exposure.  Blunt dissection and 
electrical cautery were used to expose the aorta. Two groups of eight 
subcutaneous ECG electrodes were tunneled in four quadrants surrounding the 
chest incision and connected to the device externally. To track lead migration, the 
leads were secured beneath the cutaneous layer using surgical staples which 
were used as a placement reference (Figure 8). Three standard epicardial leads 
(Medtronic, 5071 Screw-In Leads 53 cm long) were also implanted into the 
epicardium for future waveform comparison  [15]. Heparin was given to maintain 
an ACT above 250 seconds. The outflow/inflow graft was cut to ideal anatomic 
length. The aorta was partially clamped, an aortotomy was made, and the CPD 
graft was anastomosed using 3-0 Prolene suture. Hemostasis was checked and 





placed on the outflow graft and tunneled out next to the driveline for post-operative 
monitoring. A chest tube was inserted and secured for drainage.   
 
 
Figure 8. Tunneling of the subcutaneous ECG lead (red arrow, upper left). 
Surgical staples (purple arrow) being placed for subcutaneous ECG lead 
fixation and to serve as a landmark for evaluating lead migration at 
necropsy (upper right). Aortic anastomosis (lower left) and location of ECG 





After CPD implant procedure, the calves were transferred to the post-
operative care area and monitored continuously for 30 days or until the study 
was terminated under order of the attending veterinarian for pain management 
reasons. Following admission to post-operative recovery, subcutaneous and 





signals were conditioned using the CPD driver (iPulse, Abiomed, Danvers, MA). 
The waveforms were collected at 400 Hz (National Instruments, AT-MIO-16E-10, 
Austin, TX), and were filtered using a clinical standard 60 Hz notch filter 
(Frequency Devices, Ottawa IL). All waveforms were visualized and recorded 





After 30 days of device usage and data acquisition, calves were examined 
under fluoroscopy, heparinized, and subsequently euthanized with a bolus of 
Beuthanasia solution (30ml I.V.) followed by two boluses of KCl (30mEq). This 
procedure is in accordance with the recommended practices of the 2007 American 
Veterinary Medical Association Guidelines on Euthanasia. The calves were 
immediately exsanguinated and a full necropsy was performed for each calf to 
detect the occurrence of internal adverse events or infection. To quantify lead 
migration and lead damage, the lead sensing ends were visually compared to 
their placement staples using a metric ruler and the difference was recorded. 
Photographic documentation of lead migration was captured (Figure 9). The 







Figure 9. Photograph of subcutaneous lead migration (red arrow) in calves 
at the termination of the study. Staples were placed on the skin upon lead 
implantation to be used as a reference for original lead placement. Only 





Post-euthanasia, subcutaneous and epicardial ECG waveforms from the 
collected data epochs were analyzed to compare detection rates using computer 
software (MATLAB, The Mathworks, Natick, MA). For R-wave comparison, 
waveforms were analyzed on a beat-to-beat basis using custom m-files written in 
MATLAB (Mathworks, Natick MA). The original scripts published by Warren, et al. 





subcutaneous ECG waveforms [4]. During this study, a total of two ECG 
waveforms were saved (1 epicardial, 1 subcutaneous). Therefore, the scripts were 
modified to allow for the difference in signal format. Once both ECG waveforms 
were loaded into MATLAB, every subcutaneous (test) R-wave or lack thereof was 
compared to the epicardial (control) R-wave in each data epoch and classified as a 
true positive, false positive, or false negative R-wave. The same R-wave detection 
mechanism used in the CPD driver was used when detecting and comparing R-
waves for both signals. The first function of this program aligns the first R-waves 
of the subcutaneous and epicardial waveforms to account for the difference in 
lead lengths. Although the time difference between peaks in each waveform is 
small, any misalignment could potentially lead to a hindrance in R-wave 
detection. To do this, the program searches each waveform for the first local 
maximum indicated by user input of a specific time window. Once the waveforms’ 
first QRS peaks are identified they are aligned by splicing data points from the 
beginning of the subcutaneous waveform and truncating the end of the epicardial 
waveform. Next, a 1-50 Hz (N=700) finite impulse response band-pass filter was 
implemented for optimal detection and to eliminate baseline drift. 
 
For R-wave comparison, the signals were derived to detect major 
differences in slope before and after the R-wave. The program was given a 
threshold for the first three R-waves and then a bootlegging mechanism 
propagated the detection using a percentage of the average of the last three R-





was classified as true positive. A maximum time difference of 150 ms between 
epicardial and subcutaneous ECG was used to calculate true positive in 
accordance with ANSI/AAMI EC 57 standard.  If the QRS was detected in the 
epicardial waveform, but not in the subcutaneous waveform it was classified as a 
false negative. If the QRS was detected in the subcutaneous waveform, but not in 
the epicardial waveform it was classified as a false positive. These classifications 
were used to calculate Positive Predictive Value (1) and Sensitivity (2). If a signal 
was not collected or there was electrical noise during data capture, that data epoch 
was not used in the average calculations. 
 
Positive Predictive Value (PPV) =
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
  (1) 
Sensitivity =
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒
   (2) 
 
 PPV is a representation of type I error and sensitivity is a representation of 
type II error. Of the two types of error, type I error is more detrimental for 
counterpulsation therapy. If a false R-wave is falsely detected (type I error), it 
would cause an unsynchronized filling and ejection which may increase LVEW and 
diminish coronary perfusion and advance the state of heart failure. If an R-wave is 
not detected (Type II error), the device would not fill or eject for that heart beat and 
would not adversely affect the baseline hemodynamics. If R-waves are not 





temporary ‘wash mode’, and slowly wash blood in and out of its 30 ml chamber to 




Out of the six calves that survived IHF induction, one died after CPD 
implantation before any data could be acquired, and was therefore not included 
in this summary. From the remaining five calves, 791 data epochs were 
measured and recorded for chronic IHF calves (n=4) and control (n=1). 
Subcutaneous leads provided 98.8% PPV and 98.8% sensitivity when compared 












1 30-day 347 18975 0.994 ± 0.023 0.985 ± 0.047 
2 10-day 71 4429 0.996 ± 0.014 0.988 ± 0.034 
3 6-day 27 1371 0.978 ± 0.041 0.958 ± 0.074 
4 30-day 289 15168 0.985 ± 0.030 0.995 ± 0.021 
5 30-day 57 2829 0.967 ± 0.048 0.981 ± 0.046 
Totals Chronic 791 42772 0.988 ± 0.030 0.988 ± 0.040 
Table 2. Positive predictive value (PPV) and sensitivity of R-wave detection 
calculated from subcutaneous ECG recordings. Each data epoch consists 
of 30 seconds of ECG signaling. Values are listed as mean ± standard error. 
 
An example of acquired subcutaneous and epicardial waveforms are 
shown in Figure 10. One chronic calf was euthanized ten days after CPD implant 





died from heart failure symptoms six days after CPD implant. The accumulated 
epochs offered a total of 416.5 minutes of recorded ECG waveforms.  
 
 
Figure 10. Subcutaneous (dashed line) ECG demonstrated a 98.9% PPV and 
98.9% sensitivity for counterpulsation timing compared to epicardial (solid 




Lead migration (n=1, >0.05 cm) and lead fracture (n=1) were only 




Upon inspection of the recorded ECG signals, electrical noise was found. 
However, if a QRS complex could be seen visually, then custom m-files were 
used to compare R-wave detection rates. After excluding incomplete data epochs 





indiscernible waveforms), subcutaneous ECG leads were found to have a 98.8% 
PPV and 98.8% sensitivity. False positive and false negative beats were 
calculated in comparison to the epicardial lead ECG signal and not the actual 
myocardial contraction. Thus, even if the subcutaneous lead correctly picked up 
the ECG signal but epicardial lead was erroneous and vice versa, it still 
registered as a false positive and false negative, reducing PPV and sensitivity 
values for the subcutaneous leads. Despite these limitations, the performance of 
the epicardial ECG leads exceeded the design specifications of 95% PPV and 
95% sensitivity. These results demonstrate that the subcutaneous leads are 
equivalent to epicardial leads for counterpulsation device triggering and R-wave 
detection. Noise and motion artifacts don’t significantly alter the detection rate.  
 
Two of 40 subcutaneous leads had a migration or fracture. However, in 
the case of a loss in signal or reduced signal strength, the controller 
automatically switches to another lead pair for ECG signaling. This provides 
redundancy and the detection algorithm embedded in the CPD driver 
automatically picks the best ECG signal available for device timing [39]. 
Therefore, lead migration and fracture did not diminish the efficacy of the CPD 
due to the redundant design.  
 
Adverse events were reported by the veterinarian throughout the duration 
of the study and upon termination of the study (necropsy). There were no 





events associated with the CPD. The aortic cannulation was patent throughout 
the duration of the study. A limitation of the study was that the subcutaneous and 
epicardial signals were first input into the CPD driver for processing, filtering, and 
amplification before being output into the GLP compliant DAQ which removes the 
ability to analyze raw signals, and increases the opportunity for noise to distort 


























The two objectives of this study were to 1) demonstrate acute 
subcutaneous lead efficacy in providing reliable cardiac signaling for proper device 
triggering and 2) demonstrate feasibility of aortic CPD cannulation under 








Reason for Termination 
1 12/6/13 12/6/13 full term 
2 12/9/13 12/9/13 full term 
3 3/18/14 3/18/14 full term 
4 5/6/14 5/6/14 died during surgery 
5 3/14/14 3/14/14 full term 
Table 3. Summary of acute calves used for ECG lead testing and 
hemodynamic testing. 
 
For this study, an acute, non-HF model was used (n=5). CPD, 
subcutaneous leads, and epicardial leads were implanted along with pressure and 
flow sensors for hemodynamic waveform acquisition. ECG and hemodynamic 
waveforms were simultaneously collected during normal and pharmacologically 
induced hypertension, hypotension, and heart failure test conditions. At the end of 








MATERIALS AND METHODS 
 
Following the CPD implantation procedures outlined previously (Chapter 3), 
14 lines of instrumentation were implanted before the CPD was implanted in 
preparation for hemodynamic testing. Specifically, fluid-filled catheters were 
inserted into the left carotid artery and left jugular vein to acquire arterial pressure 
(ArtP) and central venous pressure (CVP), respectively. High fidelity pressure 
catheters (Millar Instruments, Houston, TX) were used to measure left atrial 
pressure (LAP) and aortic pressure (AoP). Left ventricular pressure (LVP) and left 
ventricular volumes (LVVol) were collected using a volume conductance catheter 
(Transonic Systems Inc., Ithaca, NY). Transit time flow probes (Transonic Systems 
Inc., Ithaca NY) of varying sizes were used to obtain flow waveforms. Flow probes 
were covered with transonic signal enhancement liquid and then wrapped around 
the left carotid artery (CdAF), left main coronary artery (CAF), aorta proximally to 
the heart (AOFp), aorta distally from the heart (AOFd), and pulmonary artery 
(PAF). The electrical cardiac signals (subcutaneous, epicardial, and surface) were 
also routed to the DAQ to be acquired for future use. External ECG leads were 
used only for intra-operative monitoring. All lines of instrumentation except surface 
ECG electrodes were tunneled out of the lower thoracic cavity of each bovine and 
connected to the custom GLP DAQ. Both of the implanted ECG lead systems were 
routed directly into the CPD driver to be used for synchronized device triggering. 






Hemodynamic waveforms were captured and recorded during: (1) normal 
(mean arterial pressure between 65 - 120 mmHg); (2) hypotension (mean arterial 
pressure < 65 mmHg induced by Nitroprusside); (3) hypertension (mean arterial 
pressure > 120 mmHg induced by Phenylephrine); and (4) heart failure (a 50% 
decrease in PAF induced by Esmolol). All conditions were allowed to normalize for 
15 minutes before data was acquired. In each condition, 30 second data sets were 
taken of no pump support, 1:2 support, and 1:1 support. Experiments ended with 
euthanasia and a full necropsy to detect adverse events totaling experiment time 
from 6 to 8 hours. Complete photographic documentation of adverse events was 
recorded.  
 
After the calf was euthanized, the Millar catheters and the Transonic 
Systems Inc. pressure-volume catheters were calibrated using a sealed pressure 
chamber at -5mmHg, 50mmHg, 100mmHg, and 150mmHg. The Transonic flow 
probes were calibrated electronically in a stagnant bowl of saline at 0 and 1 
Volts.  
 
All waveforms were saved using the GLP compliant DAQ system. For 
ECG waveforms, post-processing was performed as described in chronic 
experiments (Chapter 3). For hemodynamic waveforms, post-processing was 
performed using computer software (MATLAB, The Mathworks, Natick, MA). 
Specifically, Hemodynamic Evaluation and Assessment Tool (HEART) was used 





were input into the program to calculate heart rate (HR), stroke volume (SV), 
cardiac output (CO), mean coronary artery flow (CAFm), left ventricular peak 
systolic pressure (LVPSP), left ventricular end diastolic pressure (LVEDP), left 
atrial pressure (LAP), left ventricular end systolic volume (LVVes), left ventricular 
end diastolic volume (LVVed), LVEW, mean aortic pressure (AoPm), and aortic 
pulse pressure (AoP pulse). All parameters were averaged to establish one 
mean value and were subsequently analyzed in Minitab (Minitab Inc., State 
College, PA). Two-tailed paired t-tests were used to compare no support to 1:1 
support at each induced pharmacologic condition. A P-value of 0.05 or a 




Out of the four calves that survived cardiac surgery, only two had 
epicardial and subcutaneous waveforms with distinguishable QRS complexes. 42 
data epochs were measured and recorded in these two calves. The 
subcutaneous leads had a 99.7% PPV and 100% sensitivity compared to 
epicardial leads (Table 4).  
 
The CPD cannulated to the aorta diminished left ventricular (LV) external 
work (up to 31%), LV end diastolic volume by 31ml (247ml vs 278.2ml at 
baseline) and end systolic volumes by 42ml (139.2ml vs 181.2ml at baseline) 





pulse pressures, and mean coronary artery flow were augmented by up to 
17.9%, 13.0%, 62.3%, and 52.4%, respectively (Table 5). The hemodynamic 
benefits of the CPD were not as profound for normal, hypotension and 
hypertension test conditions compared to HF test condition.  
 
 
Table 4: Positive predictive value (PPV) and sensitivity of R-wave detection 
calculated from intra-operative subcutaneous ECG recordings. Each data 
epoch consists of 30 seconds of ECG signaling. Values are listed as mean 












1 1-day 16 697 0.993 ± 0.018 1.000 ± 0.000 
2 1-day 23 1145 1.000 ± 0.000 1.000 ± 0.000 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pressure-volume loop figures represent the LVEW and ventricular 
hemodynamic conditions during heart failure, hypertension, hypotension, and 
normal test conditions (Figures 11, 13, 15, 17). LVP, AoP, and CAF waveforms 
demonstrate changes in perfusion and pulsatility between each test condition 
(Figures 12, 14, 16, 18). The hemodynamic benefits from heart failure show the 
most significant improvement with CPD support (Figures 11-12). CPD support 
diminished LVEW, left ventricular end systolic and end diastolic volumes, and 
augmented coronary perfusion, aortic pressures and aortic pulsatility during heart 
failure (Figures 11-12). The hemodynamic benefits of CPD support were not 
statistically discernable from baseline values. 
 
Figure 11. Pressure-volume loops obtained from an acute animal study at 
baseline (solid, no CPD support), and 1:1 CPD support (dashed) during a 
pharmacologically induced heart failure test condition. These PV loops 
demonstrate the reduction in LVEW, end systolic volume, and end diastolic 







Figure 12. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and 
coronary artery flow waveforms obtained during a pharmacologically 
induced heart failure test condition at baseline (no CPD support), 1:2 
support, and 1:1 support. These waveforms indicate a lower ventricular 
ejection pressure and higher aortic diastolic pressures (arrows, top) and 









Figure 13. Pressure-volume loops obtained at baseline (solid, no CPD 
support) and 1:1 CPD support (dashed) during a pharmacologically 
induced hypertension test condition. The hemodynamic benefits such as 
reductions in LVEW, end systolic volume, and end diastolic volume are not 
evident compared to the heart failure test condition as the stroke volume of 
the native heart (135 ml) was much greater than the counterpulsation 







Figure 14. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and 
coronary artery flow waveforms obtained during a pharmacologically 
induced hypertension test condition at baseline (no CPD support), 1:2 
support, and 1:1 support. The hemodynamic benefits such as lower 
ventricular ejection pressure and higher aortic diastolic pressures (arrows, 
top) and coronary artery flow (arrows, bottom) are not evident compared to 
the heart failure test condition as the stroke volume of the native heart (135 







Figure 15. Pressure-volume loops obtained at baseline (solid, no CPD 
support), and 1:1 CPD support (dashed) during a pharmacologically 
induced hypotension test condition. The hemodynamic benefits such as 
reductions in LVEW, end systolic volume, and end diastolic volume are not 
evident compared to the heart failure test condition as the stroke volume of 
the native heart (82 ml) was much greater than the counterpulsation device 








Figure 16. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and 
coronary artery flow waveforms obtained during a pharmacologically 
induced hypotension test condition at baseline (no CPD support), 1:2 
support, and 1:1 support. These waveforms indicate a lower ventricular 
ejection pressure and higher aortic diastolic pressures (arrows, top) and 







Figure 17. Pressure-volume loops at baseline (solid, no CPD support), and 
1:1 CPD support (dashed) during a normal test condition. The 
hemodynamic benefits such as reductions in LVEW, end systolic volume, 
and end diastolic volume are not evident compared to the heart failure test 
condition as the stroke volume of the native heart (128 ml) was much 








Figure 18. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and 
coronary artery flow waveforms obtained during a normal test condition at 
baseline (no CPD support), 1:2 support, and 1:1 support. Lower ventricular 
ejection pressure and higher aortic diastolic pressures (arrows, top) and 
coronary artery flow (arrows, bottom) during counterpulsation support are 
not as evident compared to the heart failure test condition as the stroke 
volume of the native heart (128 ml) was much greater than the 












The >99% PPV and sensitivity values demonstrated that the epicardial 
leads can adequately trigger the CPD during a wide range of physiologic 
conditions. Hemodynamically, cardiac output, coronary perfusion, aortic 
pressure, and aortic pulsatility showed an increasing trend and decreases were 
observed in end-systolic and end-diastolic left ventricular volumes and LVEW. 
The benefits of counterpulsation are most pronounced when counterpulsation 
device volume is similar to the stroke volume of the native heart and at low aortic 
compliances [41]. The hemodynamic waveforms from the animal study closely 
resembles couterpulsation waveform morphology observed clinically and in an 
earlier computer simulation study [42]. However, the hemodynamic benefits of 
CPD support was not evident at normal, hypertensive, and hypotensive 
conditions in the acute animal study as the stroke volume of the native heart 
(128, 135, and 82 ml respectively) was much greater than the counterpulsation 
device volume (30 ml). Further, the aortic compliance of a calf is significantly 
greater than that of a human with HF [41]. Due to these factors and low sample 
size (n=3), statistical significance could not be ascertained between baseline and 
1:1 CPD support, but improving hemodynamic trends with CPD support 
demonstrate the feasibility of aortic cannulation. While aortic anastomosis would 
increase the invasiveness of device implantation in patients with small subclavian 
arteries, chronic counterpulsation may enable earlier intervention (Class III) and 





The hemodynamic benefits provided by the CPD anastomosed to the 
aorta would be slightly higher than the benefits provided by the CPD 
anastomosed to the subclavian artery due to energy losses associated with the 
CPD being farther away from the aorta [21]. The hemodynamic parameters of the 
CPD anastomosed to the carotid artery in an acute bovine model (n=12) from an 

















Normal Baseline   78 ± 4 8.0 ± 0.0 207 ± 46 103 ± 3 16 ± 2 14 ± 2 
Hypertension Baseline   73 ± 4 8.1 ± 0.5 285 ± 43 138 ± 3 19 ± 2 14 ± 2 
  CPD 1:2 77 ± 5 8.2 ± 0.6 305 ± 49 138 ± 3 19 ± 3 15 ± 2 
    1:1 76 ± 4 8.2 ± 0.6 314 ± 49 137 ± 3 19 ± 2 14 ± 2 
Hypotension Baseline   70 ± 3 6.8 ± 0.5 141 ± 33 77 ± 2 11 ± 1 9 ± 1 
  CPD 1:2 72 ± 3 6.8 ± 0.7 155 ± 33 76 ± 2 10 ± 1 9 ± 1 
    1:1 71 ± 3 6.8 ± 0.6 173 ± 43 74 ± 2 10 ± 1 8 ± 1 
Heart Baseline   66 ± 3 6.0 ± 0.3 139 ± 35 89 ± 5 22 ± 1 15 ± 1 
Failure CPD 1:2 67 ± 3 6.2 ± 0.3 153 ± 36 88 ± 5 22 ± 1 16 ± 1 
    1:1 67 ± 3 6.1 ± .03 159 ± 37 84 ± 4 21 ± 1 15 ± 1 
TABLE 6. Hemodynamic parameters during acute counterpulsation 
therapy with the CPD  cannulated to carotid artery in calves with 
pharmacologically induced hypertension, hypotension, and heart 
failure [1]. 
 
A limitation of the study is that the hemodynamic effects were observed 
under pharmacologically induced, acute conditions. Thus, the state of the animal 
was never completely stable due to the half-life of drugs. Chronic pathologies or 
a significantly higher sample size (n=10-12) may be required for demonstrating 







CHAPTER 4 - CONCLUSION 
 
 
This study demonstrates the long-term efficacy of using subcutaneous 
leads to provide an accurate, reliable ECG waveform for R-wave detection to 
trigger counterpulsation devices shown by 98.9% PPV and 98.9% sensitivity for 
all test conditions. Since the adverse events associated with lead migration and 
lead fracture didn’t impact device triggering, use of subcutaneous leads in future 
clinical therapies is promising. Additionally, this study demonstrates the feasibility 
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Academic and Professional Experience 
2013-2015 Three Academic Research Co-ops, Advanced Heart Failure 
Research at the Cardiovascular Innovation Institute (total: 1 year) 
 Provided technical support for many grant and industry sponsored studies, 
including hemolysis testing for mechanical circulatory support devices. 
 Assisted with instrumentation and data collection during open-heart surgery 
on calves.  
 Observed VAD operations and collected myocardial samples for a tissue 
repository. 
 Learned techniques related to instrument preparation & handling, inducing 
anesthesia, cardiac defibrillation, tissue procurement, tissue transportation & 
storage, administering regional blood flow microspheres, fluoroscopy exams, 
skin electrocautery & suturing, electrocardiograms, and hemodynamic exams. 
 
2014  Part-time University of Louisville Employment, Tutoring 
 Tasked with helping college students understand mathematical concepts and 
techniques from basic Algebra to Calculus II 
2012-2013 Part-time University of Louisville Employment, Test Grader 
 Tasked with grading Calculus tests and assessing depth of knowledge for 
Calculus I, II, and III material 
2010-2011 Part-time Kroger Employee, Courtesy Clerk 
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Trustees Academic Scholarship Fall 2011 - Spring 2016 
Dean’s List Spring 2014 
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2. Schumer E, Monreal G, Carnahan S, Sobieski M, Slaughter M. Venovenous 
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3. Schumer E, Monreal G, Carnahan S, Sobieski M, Slaughter M.  Outcomes for 
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KMA, 2014. (published) 
 
Extracurricular Activities, Volunteer Experience, Leadership Activities 





 Palmetto Medical Initiative, based in Charleston, SC, is an organization that 
sends medical missionaries to underserved populations in Nicaragua and 
Uganda. The medical care team that I served with provided a range of 
services including the distribution of prescription drugs and providing patients 
with education, reading glasses, wound care, physical therapy, and 
Counseling. I secured over $3000 in private funding for this mission. I spent 
most of my time on the trip distributing the pharmaceuticals and teaching our 
patients how to take each individual medicine, with the help of an interpreter. 
 
Member of Biomedical Engineering Society     2011-2014 
 
Campus Crusaders for Christ (CRU) 2011-2014 
 Served as a worship leader during weekly meetings 
 
Church Related Service  2001-present 
 I have identified myself as a Christian all of my life; consequently, I would feel 
hypocritical if I didn’t try to serve others the way Christ serves his people. 
Over the past few years, I have served people in the church and outside the 
church through various organizations. I have served them by giving my most 
valuable resources such as time and money to organizations such as 
HOPEMOB, Eyes That See, Habitat for Humanity (H4H), Palmetto Medical 
Initiative, etc. I have personally given my time to all of these different 





people around me by watching their kids for them, leading them in worship 
during church, or feeding people that would otherwise go hungry.  
Hobbies 
2009-Present Snowboarding/Water Skiing 
 Snow sports and water sports have been a passion of mine ever since I 
was a little boy. However, seeing and riding the slopes of Kalispell, Montana is 
what really sparked a life-long passion in me to snowboard. There is nothing 
better than to fly down a mountain without another care in the world. 
 
2007-Present   Playing Piano/Singing 
 Every person that has ever heard me play piano has told me I have a gift 
for music. In fact, acceptance to the prestigious Governor’s School of the Arts is 
primarily what allowed me to receive a Trustees Scholarship at the University of 
Louisville for my undergraduate and graduate degrees. In addition, I have 
accompanied for pay during various instrumental workshops and weddings. I 
have also volunteered my services to many non-profit organizations. 
 
2011-Present   Ultimate Frisbee 
  I have always had a strong body and when I came to college I found 
Ultimate Frisbee to be a very good fit for me. It is a highly competitive, safe, non-
contact, and fun sport, but the best feature is how it keeps me fit from all of the 
running involved. Other Interests and Hobbies: Backpacking, camping, healthy 
living, reading, medicine, soccer, landscaping, and traveling.  
